FundedIQ
Biotechnology

MiNA Therapeutics: Funding, Investors & Team (Sep 2026)

MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms. Its technology helps transform the therapy landscape of cancer and other severe diseases that enable doctors and physicians to cure diseases and develop medicines that restore normal function to patients' cells. The company was founded in 2008 and is headquartered in London, England.

www.minatx.com LinkedIn London, United Kingdom 11-50 employees
Biotechnology Genetics Life Science Pharmaceutical
Total raised
$38.0M
Rounds
2
Latest
Corporate Round
Jul 2021

MiNA Therapeutics has raised $38.0M across 2 funding rounds on record, the most recent a Corporate Round of $15.0M announced in Jul 2021.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

MiNA Therapeutics Company Profile and Key Stats

Total funding raised
$38.0M
across 2 rounds on record
Funding rounds on record
2
Latest funding round
Corporate Round
$15.0M in Jul 2021
Employees
11-50
reported band
Headquarters
London, United Kingdom

Latest funding round on record: Jul 2021.

MiNA Therapeutics Funding Rounds

Date
Round
Amount
Corporate Round
$15.0M
Undisclosed round
$23.0M

MiNA Therapeutics raised $23.0M in an undisclosed round announced in Sep 2020.

10 months later, a Corporate Round of $15.0M was announced in Jul 2021.

MiNA Therapeutics Founders and Leadership Team

Name
Role
Contact
Robert Habib
CEO
Locked

Contact details for the MiNA Therapeutics team: 1 of 1 has an email address on file.

Start 14-day free trial →

MiNA Therapeutics Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round

MiNA Therapeutics' latest round of $15.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like MiNA Therapeutics in Biotechnology and London

Companies Similar to MiNA Therapeutics

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…

Series A $33.6M

Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…

Undisclosed round $3.5M

Concert Bio helps businesses create optimal microbial communities.

Undisclosed round $130k

RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…

Series A $113M

N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…

Undisclosed round $3.6M

Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…

Undisclosed round $3.0M

Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.

Series A $32.5M

IMU is a discovery engine mapping the immune system to advance precision medicine.

Series A $38.4M

Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…

Undisclosed round $5.4M

Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…

Undisclosed round

Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…

Pre-Seed $740k

Five is a biometric payment services company that offers thumb recognition technology for safe transactions.

Seed $6.0M

MiNA Therapeutics Funding FAQs

What does MiNA Therapeutics do?

MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms. Its technology helps transform the therapy landscape of cancer and other severe diseases that enable doctors and physicians to cure diseases and develop medicines that restore normal function to patients' cells. The company was founded in 2008 and is headquartered in London, England.

How much funding has MiNA Therapeutics raised?

MiNA Therapeutics has raised $38.0M across 2 rounds on record. The most recent is a Corporate Round of $15.0M announced in Jul 2021.

When did MiNA Therapeutics last raise funding?

MiNA Therapeutics' most recent funding round on record is a Corporate Round of $15.0M, announced in Jul 2021.

Who is the CEO of MiNA Therapeutics?

Robert Habib is listed as CEO at MiNA Therapeutics.

Where is MiNA Therapeutics headquartered?

MiNA Therapeutics is based in London, England, United Kingdom.

How many employees does MiNA Therapeutics have?

MiNA Therapeutics is in the 11-50 employee band.

How does MiNA Therapeutics' funding compare to other Biotechnology startups?

MiNA Therapeutics' latest round of $15.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's MiNA Therapeutics Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for MiNA Therapeutics is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.